Properties of the estimated variance component for subject-by-formulation interaction in studies of individual bioequivalence

Statistics in Medicine

Volumn 19, Issue 20, 2000, Pages 2867-2878

  Endrenyi, Laszlo ^a   Taback, Nathan ^a   Tothfalusi, Laszlo ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOEQUIVALENCE; BIOSTATISTICS; DRUG BIOAVAILABILITY; DRUG FORMULATION; FOOD AND DRUG ADMINISTRATION; HUMAN; MAXIMUM LIKELIHOOD METHOD; STATISTICAL ANALYSIS; STATISTICAL PARAMETERS;

CROSS-OVER STUDIES; HUMAN; MODELS, STATISTICAL; THERAPEUTIC EQUIVALENCY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0034735583     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0258(20001030)19:20<2867::AID-SIM551>3.0.CO;2-J     Document Type: Article

References (22)

1. Considerations of individual bioequivalence
2. Draft Guidance for Industry. In vivo bioequivalence studies based on population and individual bioequivalence approaches
3. Individual bioequivalence - New concepts in the statistical assessment of bioequivalence metrics
4. Case studies, practical issues and observations on population and individual bioequivalence
5. A method for the evaluation of individual bioequivalence
6. A simple approach for the evaluation of individual bioequivalence
7. On population and individual bioequivalence
8. Towards a practical strategy for assessing individual bioequivalence
9. The assessment of individual and population bioequivalence
10. Subject-by-formulation interaction in determinations of individual bioequivalence: Bias and prevalence
11. Current issues in bioequivalence trials
12. Discussion of individual bioequivalence by M.-L
13. Individual bioequivalence - A European perspective
14. Individual bioequivalence - Has its time come?
15. Mean difference vs. variability reduction: Trade-offs in aggregate measures for individual bioequivalence
16. Individual and average bioequivalence of highly variable drugs and drug products
17. Asymmetry of the mean-variability tradeoff raises questions about the model in investigations of individual bioequivalence
18. A parametric confidence interval for a moment-based scaled criterion for individual bioequivalence
19. Individual bioequivalence: Attractive in principle, difficult in practice